Abstract
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 410-413 |
| Number of pages | 4 |
| Journal | Netherlands Journal of Medicine |
| Volume | 74 |
| Issue number | 9 |
| Publication status | Published - Nov 2016 |
| Externally published | Yes |
Keywords
- Complete remission
- Endometrial cancer
- Endometrial carcinoma
- Pazopanib
- Tyrosine kinase inhibitor
Fingerprint
Dive into the research topics of 'An impressive response to pazopanib in a patient with metastatic endometrial carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver